Loading
Lung Cancer Treatments and Mutations · Journal article
Main Group Chemistry · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is an early-stage medicinal chemistry study reporting design, synthesis, and in silico evaluation of three novel chalcone derivatives, followed by in vitro cytotoxicity screening of the lead compound against a lung cancer cell line. The lead compound (2E)-1-(23,4-trichlorophenyl)-3-(24,5-trimethoxyphenyl)prop-2-en-1-one showed selective toxicity to A549 cells and induced apoptosis, but the work remains preclinical with no in vivo data, pharmacokinetics, or clinical relevance established.
In vitro cytotoxicity screening with computational molecular docking and dynamics modelling. A549 non-small cell lung cancer cell line and normal human fibroblasts (in vitro; no patient or animal data). Intervention: Three chalcone derivatives; lead compound (2E)-1-(23,4-trichlorophenyl)-3-(24,5-trimethoxyphenyl)prop-2-en-1-one evaluated for cytotoxicity, apoptosis, and cell cycle effects. Compared with: Normal fibroblasts used as a comparator cell type for selectivity; no pharmacological control or reference drug tested.
Lead chalcone derivative achieved docking score of −8.6 kcal/mol against VEGFR2 kinase domain Molecular dynamics simulation showed stability of lead compound–VEGFR2 complex over 200 ns MTT assay revealed IC50 of 29.03 µg/ml in A549 lung cancer cells versus IC50 of 67.54 µg/ml in normal fibroblasts
No in vivo efficacy or safety data provided; cell line studies alone do not predict clinical activity
This work provides early chemical scaffolding for VEGFR2 inhibition in NSCLC but is too preliminary to inform clinical practice. Advancement requires in vivo tumour models, pharmacokinetic and safety profiling, and mechanistic validation before any consideration of clinical development.
Early-phase in vitro study with computational support showing a novel chalcone derivative has selective cytotoxicity and apoptosis induction in lung cancer cells, but lacks in vivo validation, clinical data, and comparative controls needed to establish therapeutic potential.
As stated by the source record.
Quoted from the source exactly as published.
This work provides early chemical scaffolding for VEGFR2 inhibition in NSCLC but is too preliminary to inform clinical practice. Advancement requires in vivo tumour models, pharmacokinetic and safety profiling, and mechanistic validation before any consideration of clinical development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This study aimed to explore the therapeutic potential of new chalcone derivatives for non-small cell lung cancer (NSCLC) in depth via multiple methods, including design, synthesis, in silico, and in vitro studies. Three chalcone derivatives, (2E)-1-(3,4-dichlorophenyl)-3-(thiophen-2-yl)prop-2-en-1-one,(2E)-1-(3,4-dichlorophenyl)-3-(3-methylthiophen-2-yl)prop-2-en-1-one, and (2E)-1-(23,4-trichlorophenyl)-3-(24,5-trimethoxyphenyl)prop-2-en-1-one, were synthesized via Claisen-Schmidt condensation and characterized via Fourier transform infrared (FT-IR) spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, and thermal analysis. Molecular docking studies were subsequently carried out against the vascular endothelial growth factor receptor 2 (VEGFR2) kinase domain (PDB ID: 4ASD), which has favorable docking scores: the ligand with the best docking score of −8.6 kcal/mol was (2E)-1-(23,4-trichlorophenyl)-3-(24,5-trimethoxyphenyl)prop-2-en-1-one. Molecular dynamics simulation of this complex (4ASD-(2E)-1-(23,4-trichlorophenyl)-3-(24,5-trimethoxyphenyl)prop-2-en-1-one) revealed that it remained stable for a period of 200 ns. Qualitative structure–activity relationship (SAR) investigation discovered that donor–acceptor substitution configurations in -(2E)-1-(23,4-trichlorophenyl)-3-(24,5-trimethoxyphenyl)prop-2-en-1-one) boost the biological activities, which is validated by kinase inhibitor prediction based on PASS prediction. The MTT assay revealed that (2E)-1-(23,4-trichlorophenyl)-3-(24,5-trimethoxyphenyl)prop-2-en-1-one selectively induced toxicity in the A549 lung cancer cell line (IC 50 = 29.03 µg/ml) compared with normal fibroblasts (IC 50 = 67.54 µg/ml). Flow cytometry-based apoptosis and cell cycle studies confirmed its ability to induce apoptosis (29.6%) and cell cycle arrest at the sub-G1 phase. These promising results from computational and experimental studies underscore the potential of chalcone derivative (2E)-1-(23,4-trichlorophenyl)-3-(24,5-trimethoxyphenyl)prop-2-en-1-one to serve as an excellent therapeutic agent in Non-Small Lung Cancer Cells (NSCLC) therapy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.